1. Home
  2. PFL vs RIGL Comparison

PFL vs RIGL Comparison

Compare PFL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFL
  • RIGL
  • Stock Information
  • Founded
  • PFL 2003
  • RIGL 1996
  • Country
  • PFL United States
  • RIGL United States
  • Employees
  • PFL N/A
  • RIGL N/A
  • Industry
  • PFL Finance Companies
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFL Finance
  • RIGL Health Care
  • Exchange
  • PFL Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • PFL 349.9M
  • RIGL 298.0M
  • IPO Year
  • PFL N/A
  • RIGL 2000
  • Fundamental
  • Price
  • PFL $8.11
  • RIGL $17.54
  • Analyst Decision
  • PFL
  • RIGL Buy
  • Analyst Count
  • PFL 0
  • RIGL 5
  • Target Price
  • PFL N/A
  • RIGL $36.80
  • AVG Volume (30 Days)
  • PFL 113.7K
  • RIGL 222.1K
  • Earning Date
  • PFL 01-01-0001
  • RIGL 05-06-2025
  • Dividend Yield
  • PFL 11.53%
  • RIGL N/A
  • EPS Growth
  • PFL N/A
  • RIGL N/A
  • EPS
  • PFL N/A
  • RIGL 0.99
  • Revenue
  • PFL N/A
  • RIGL $179,278,000.00
  • Revenue This Year
  • PFL N/A
  • RIGL $12.53
  • Revenue Next Year
  • PFL N/A
  • RIGL $15.68
  • P/E Ratio
  • PFL N/A
  • RIGL $17.36
  • Revenue Growth
  • PFL N/A
  • RIGL 54.71
  • 52 Week Low
  • PFL $6.98
  • RIGL $7.48
  • 52 Week High
  • PFL $8.62
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • PFL 45.48
  • RIGL 44.84
  • Support Level
  • PFL $7.73
  • RIGL $16.05
  • Resistance Level
  • PFL $8.13
  • RIGL $17.52
  • Average True Range (ATR)
  • PFL 0.24
  • RIGL 1.26
  • MACD
  • PFL 0.00
  • RIGL 0.10
  • Stochastic Oscillator
  • PFL 67.57
  • RIGL 63.57

About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest

PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: